Displaying drugs 13951 - 13975 of 15377 in total
BB 21217
BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as idecabtagene vicleucel (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP) for memory-like T cells.
Investigational
Vixtimotamab
Investigational
Belagenpumatucel-L (SK-LU-1)
Investigational
MRG-003
MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
A166
A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker.
Investigational
AAV-AQP1
Investigational
Ozuriftamab vedotin
Investigational
Deoxynucleogene ancparvovec
Investigational
AML-2-23
Investigational
CypCaps
Investigational
DNP-Modified autologous tumor vaccine
Investigational
Myb34.5
Investigational
Albumin-stabilized nanoparticle (130 nm)
Investigational
Boserolimab
Investigational
CD8+ enriched young tumor infiltrating lymphocytes
Investigational
TASO-001
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
CD-16 NK-92 cells
Investigational
LP-2307
LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.
Investigational
APL-502
APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).
Investigational
Anselamimab
Investigational
Casdozokitug
Investigational
Batiraxcept
Investigational
ETBX-051
Investigational
GCS-100
Investigational
Displaying drugs 13951 - 13975 of 15377 in total